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Objective: The objective of this study is to understand the characteristics of older adults on newly
prescribed psychotropic medication with minimal psychiatric symptoms.
Methods:Naturalistic cohort study of non-institutionalized older adults in Pennsylvania participating in
the Pharmaceutical Assistance Contract for the Elderly. Persons newly prescribed antidepressant or
anxiolytic monotherapy or combination therapy were contacted for clinical assessment by a
telephone-based behavioral health service. The initial assessment included standardized mental health
screening instruments and scales including the Blessed Orientation-Memory-Concentration test,
Patient Health Questionnaire-9, Generalized Anxiety Disorder-7, and Medical Outcomes Survey (SF-12).
In addition, patients were asked for their understanding of the prescription indication.
Results: Of the 254 participants who met minimal symptom criteria (Patient Health Questionnaire-
9< 5 and Generalized Anxiety Disorder-7< 5), women comprised slightly more of the anxiolytic
compared with antidepressant monotherapy group (88.9% vs. 76.7%, p=0.04). The most common self-
reported reason for prescription of an antidepressant or anxiolytic was depression or anxiety, respectively,
despite near-absence of these symptoms on clinical assessment. Comparing monotherapy to combination
therapy groups, those with combination therapy were more likely to report a history of depression (12.6%
vs. 1.8%, p< 0.001) and also report depression as the reason for the prescription (40.2% vs. 21.0%, p< 0.01).
Conclusions: In this sample of older adults on new psychotropic medication with minimal psychiatric
symptoms, there are few patient characteristics that distinguish those on antidepressant versus
anxiolytic monotherapy or those on monotherapy versus combination therapy. While quality of care
in late-life mental health has focused on improving detection and treatment, there should be further
attention to low-symptom patients potentially receiving inappropriate pharmacotherapy. Copyright
# 2014 John Wiley & Sons, Ltd.
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Introduction
Over the past 20 years, the detection and treatment of
mental health disorders in primary care settings has
been a key area of emphasis in geriatric mental health,
and a variety of strategies have been developed to
improve detection and treatment (Unutzer et al.,
2002; Crystal et al., 2003; Oxman et al., 2003; Bruce
et al., 2004; Oslin et al., 2006a). While evidence-based
psychotherapies may be preferred by older adults
(Landreville et al., 2001; Gum et al., 2006), pharmaco-
therapy is the treatment most commonly provided
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(Young et al., 2001). Concurrent with this emphasis
on detection and treatment, evidence continues to
accumulate regarding the potential risks of psychotropic
use in older adults. The use of benzodiazepines in older
adults has been associated with increased risk of falls
and fractures (Wang et al., 2001; Chang et al., 2008).
Although the newer antidepressants have been favored
for their safety and side effect profile relative to the
tricyclic antidepressants (Zwanziger and Auerbach,
1991; Rudorfer et al., 1994; Peretti et al., 2000), the
selective-serotonin reuptake inhibitors have now been
associated with the risk of fracture (Ginzburg and
Rosero, 2009) and adverse cognitive effects (Culang
et al., 2009; Sneed et al., 2010), while mirtazapine and
venlafaxine have been associated with stroke and
fracture (Coupland et al., 2011a, 2011b). Most psycho-
tropic medications are listed as at least potentially
inappropriate in the most recent iteration of the
American Geriatrics Society Beers Criteria (American
Geriatrics Society, 2012).
The emphasis on treatment of mental health disor-
ders in primary care paired with the growing attention
to risks of psychotropic use has led to work exploring
the potentially inappropriate use of psychotropic
medication in primary care, such as prescribing in
the absence of a psychiatric disorder. Survey and
administrative data have documented the significant
use of psychotropic medication in the absence of
psychiatric diagnoses or mental health complaints
(Pagura et al., 2011; Wiechers et al., 2013), which
appears to be even more likely in older adults
(Wiechers et al., 2014; Maust et al., 2014). While these
findings are important, a limitation of these analyses is
that they do not use patient-level clinical data.
Although a diagnosis of depression may not have been
recorded, the patient in fact may have been depressed
and the clinician responded appropriately.
The Behavioral Health Laboratory (BHL) is an
evidence-based clinical service delivered by telephone
to help identify and manage the mental health needs
of patients (Oslin et al., 2006b). Since 2008, the
Commonwealth of Pennsylvania’s Pharmaceutical
Assistance Contract for the Elderly (PACE) has
contracted with BHL to provide clinical services to older
adults in Pennsylvania who have been newly prescribed
an antidepressant, anxiolytic, or antipsychotic. Based on
contact with older adults across the state, we were the
first with patient-level clinical information to describe
psychotropic use in minimally symptomatic older
adults (Maust et al., 2011).
On the basis of these baseline analyses, we decided
to prospectively identify and follow the cohort of older
adults with a minimal level of psychiatric symptoms.
This minimal symptom cohort was prospectively defined
as meeting the following three criteria: minimal symp-
toms of depression (Patient Health Questionnaire-9
[PHQ-9]< 5), minimal symptoms of anxiety (General-
ized Anxiety Disorder-7 [GAD-7]< 5), and a negative
screen for any other Axis I psychiatric disorders.
Having provided the BHL clinical service over several
additional years, the aims of these analyses were
twofold. First, we wanted to see whether our initial
findings were replicable. If so, we then wanted to gain
further understanding of the use of psychotropic
medication in minimally symptomatic older adults.
In order to do so, we examined if and how minimally
symptomatic older adults prescribed antidepressants
versus anxiolytics compared on factors such as
sociodemographics, treatment history, and current
symptoms. Next, we compared patients for whom the
index medication was the only psychotropic medica-
tion with those already receiving a psychotropic medi-
cation. We hypothesized that those on combination
psychotropic regimens would be more likely to report
previous mental health treatment and more likely to
endorse worse overall physical and emotional health.
Methods
These analyses are based on an ongoing clinical
program. The data collection methods that follow
are similar to those described in previous publications
(Maust et al., 2011, 2013a).
Sample
This cohort is drawn from low-income older adults in
the state of Pennsylvania who participate in the state’s
PACE, a program of the Pennsylvania Department of
Aging that provides comprehensive prescription
coverage for low-income residents 65 years or older.
Participants were contacted for clinical assessment by
the BHL as part of a clinical contract with the PACE
program. PACE enrollees eligible for contact were
adults in a non-institutionalized setting who filled at
least one new prescription for an antidepressant,
antipsychotic, and/or anxiolytic between August 2010
and February 2013. A prescription was considered
new if no prior pharmacy claim to PACE had
been made for that medication class in a preceding
9-month period of continuous enrollment. Enrollees
were randomly selected for the BHL clinical assess-
ment every week during this period from all claims
submitted to PACE for newly written prescriptions,
stratified by county (Philadelphia area, Allegheny area,
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and other). Stratification by county was performed to
ensure that the sample was not dominated by enrollees
in the state’s large urban centers. Prescriptions written
by providers identified by PACE as psychiatrists were
excluded from this analysis.
Enrollees sampled by PACE who agreed to
participate in the BHL clinical assessment underwent
an initial baseline telephone assessment that was
administered by staff BHL health technicians (not
otherwise involved in the enrollees’ outpatient care).
These analyses here are limited to claims for
antidepressants and anxiolytics, as these medications
may be prescribed for similar complaints.
Measures
The baseline interview included sociodemographics,
and standardized scales administered included the
following:
(1) BlessedOrientation-Memory-Concentration (BOMC)
test, range 0 to 28 where >10 suggests cognitive
impairment (Katzman et al., 1983);
(2) MINI International Neuropsychiatric Interview
(includes psychosis, mania, GAD, Panic disorder,
and alcohol abuse/dependence modules), a struc-
tured diagnostic interview for DSM-IV disorders
(Sheehan et al., 1998);
(3) PHQ-9, a brief self-report depression severity
measure based on self-report where scores of 5,
10, 15, and 20 represent mild, moderate, moder-
ately severe, and severe depression, respectively
(Kroenke et al., 2001);
(4) GAD-7, a brief self-report anxiety measure where
scores of 5, 10, and 15 reflect mild, moderate, and
severe anxiety, respectively (Kroenke et al., 2007);
(5) Medical Outcomes Survey (SF-12), a set of 12
items from the SF-36 Health Survey yielding phys-
ical and mental summary measures where the adult
population average is 50 on both the physical and
mental summary measures (Ware et al., 1996).
In addition, interviewees were asked about past
episodes of depression significant enough to interfere
with social or occupation function (Oslin et al.,
2006b). Finally, interviewees were asked for their
understanding of the reason for the index medication
(the medication that prompted contact from the
BHL). Their response was recorded as free text,
which the health technician conducting the interview
also categorized it on the basis of a brief list of
forced-choice options.
Interviews began with the BOMC; for those who
scored ≥14, the interview with the PACE enrollee
was terminated, and permission was sought to speak
with a caregiver/loved one. This analysis only includes
data from participant interviews and does not include
the caregiver interview data. After completing the
clinical interview, participants provided oral consent
to allow the use of clinical data for research purposes
in accordance with a University of Pennsylvania
Institutional Review Board-approved protocol.
Analytic plan
The analyses here are limited to those who, based on the
initial clinical contact, met the criteria for the minimal
symptom cohort (PHQ-9< 5, GAD-7< 5, and negative
screens on MINI modules). The first analyses compared
those on antidepressant or anxiolytic monotherapy; the
second compared those on any monotherapy versus
combination therapy. Descriptive univariate analyses
included calculating means and standard deviations for
continuous outcomes and calculating frequencies and
percentages for categorical outcomes. To compare
sociodemographic/background characteristics and BHL
mental health assessment outcomes across medication
class, we employedWilcoxon two-sample and chi-square
tests for continuous and categorical variables, respec-
tively. Categorical variables with small cell counts (<5)
were compared using Fisher’s exact test. Lastly, we
performed a sensitivity analysis comparing symptom
levels within treatment groups by time to contact. All
analyses were two-tailed, with a p-value ≤0.05 denoting
statistical significance. Analyses were conducted using
SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).
Results
Contact was attempted for 4907 potential participants,
of whom 1313 (26.8%) were able and willing to
complete the full core interview. One thousand three
hundred participants (26.5%) were unable to be
reached despite multiple attempts (the contact
information available to BHL was not up to date, in
many cases), 1547 (31.5%) refused, and 409 (8.3%)
were unable to complete an assessment for reasons
such as a language barrier or communication impedi-
ment (such as hearing impairment). Of the 1313 that
agreed to participate, 552 (42.0%) met the criteria
for the minimal symptom cohort. One hundred
twenty-six (9.6%) had BOMC ≥14, so only caregivers
completed an interview, whereas seven (0.5%) did not
consent to allow their information to be used for
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research purposes. Overall, the mean time to contact
was 16.6 days (standard deviation [SD] 9.8). The results
that follow are for the 254 participants (19.3%) who:
completed the core interview, met the criteria for the
minimal symptom cohort, and confirmed that the
index medication was a newly prescribed medication.
Results from the monotherapy group are presented
in Tables 1 and 2. For example, the average PHQ-9
score for enrollees newly prescribed an antidepressant
was 1.9 (SD 1.4), whereas the average GAD-7 for
enrollees newly prescribed an anxiolytic was 1.0 (SD
1.2). The only significant difference between the
antidepressant and anxiolytic groups was gender, with
the anxiolytic users even more likely to be female than
in the antidepressant group (X2(1) = 4.29, p= 0.04).
Patients’ self-report of the reason they were prescribed
the new antidepressant or anxiolytic (Table 2) gener-
ally follow medication class, where those prescribed
antidepressants were most likely to endorse symptoms
categorized as depressive (Fisher’s exact, p< 0.001)
and those on anxiolytics were most likely to report
anxiety (X2(1) = 25.26, p< 0.001). Time to contact
was 16.2 days (SD 9.8) and 17.5 days (SD 8.8) for the
antidepressant and anxiolytic groups, respectively
(Z= 0.00, p= 1.00).
Results comparing the psychotropic combination
to monotherapy groups are presented in Tables 3
and 4. The only demographic or clinical characteristic
on which they varied (Table 3) was past history of
depression, which the combination group was more
likely to endorse (p< 0.001). The combination group
was more likely to endorse depressive-type symptoms
as the reason for prescription of the new medication
(X2(1) = 10.64, p< 0.01). Otherwise, the monotherapy
and combination therapy groups did not differ signif-
icantly in self-reported reason for psychotropic pre-
scription. Time to contact was 16.8 days (SD 9.8)
and 16.1 days (SD 9.9) for the antidepressant and
anxiolytic groups, respectively (Z=0.48, p= 0.64).
Lastly, we used the median time to contact
(14 days) to split each of the four groups (antidepres-
sant and anxiolytic monotherapy; monotherapy and
combination therapy) and compare symptom burden.
There was no significant difference by speed of contact
for any of the treatment groups. For example, when
comparing depression symptoms of those on a new
antidepressant that were contacted ≤14 and >14 days
from starting the medication, there was no statistically
significant difference in PHQ-9 (1.88 [SD 1.41] vs.
1.85 [SD 1.39], respectively; Z=0.14, p= 0.89).
Discussion
In 2011, we published the first analyses with patient-
level clinical information describing the use of new
psychotropic medication in older adults despite mini-
mal psychiatric symptoms (Maust et al., 2011). In those
analyses, 48% of PACE enrollees on newly prescribed
psychotropic medication did not meet screening criteria
Table 1 Sociodemographic and clinical characteristics of Pharmaceutical Assistance Contract for the Elderly participants on antidepressant or
anxiolytic monotherapy
Characteristic
Monotherapy
n=167
Antidepressant
n=86 (51.5%)
Anxiolytic
n=81 (48.5%) Test, p-value
Age (mean, SD) 78.6 (6.6) 78.5 (6.6) 78.6 (6.6) Z=0.00, p=1.00
Female 138 (82.6) 66 (76.7) 72 (88.9) X2(1) = 4.29, p=0.04
White 156 (93.3) 79 (91.9) 77 (95.1) p* = 0.54
Financial status (has at least “enough to get by”) 157 (94.0) 80 (93.0) 77 (95.1) p* = 0.75
Married 47 (28.1) 24 (27.9) 23 (28.4) X2(1) = 0.00, p=0.94
Number of unique medications 6months prior to
index medication
7.5 (4.1) 7.4 (3.7) 7.6 (4.5) Z=0.27, p=0.78
Number of unique mediations 6months after index medication 7.0 (4.1) 7.2 (4.2) 6.8 (4.1) Z=0.63, p=0.53
Overall general functioning (SF-12): physical
component score (mean, SD)
44.6 (10.2) 43.8 (10.7) 45.4 (9.7) Z=0.99, p=0.33
Overall general functioning (SF-12): mental
component score (mean, SD)
56.7 (5.7) 56.0 (5.8) 57.4 (5.5) Z=1.54, p=0.13
In mental health care in past 2 years 2 (1.2) 0 (0) 2 (2.5) p* = 0.23
In mental health care in past 3months 1 (0.6) 0 (0) 1 (1.2) p* = 0.49
Past history of depression 3 (1.8) 2 (2.3) 1 (1.2) p*=1.00
Cognitive function (blessed score) (mean, SD) 5.0 (3.8) 5.1 (4.0) 4.9 (3.4) Z=0.09, p=0.93
PHQ-9 score (mean, SD) 1.9 (1.4) 1.9 (1.4) 1.8 (1.4) Z=0.35, p=0.73
GAD-7 score (mean, SD) 0.8 (1.1) 0.7 (1.0) 1.0 (1.2) Z=1.32, p=0.19
PHQ-9, Patient Health Questionnaire-9; GAD-7, Generalized Anxiety Disorder-7; SD, standard deviation.
*Fisher’s exact test.
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for any psychiatric disorder. Therefore, the first aim of
these analyses was to replicate this surprising finding.
While slightly lower, of those PACE enrollees that
agreed to participate, we found that 42% of those on a
newly prescribed psychotropic medication were
essentially asymptomatic. We then conducted analyses
considering those on psychotropic monotherapy versus
combination therapy in order to gain some additional
understanding of the phenomenology of prescribing to
these minimally symptomatic older adults. Ultimately,
we found very little to distinguish the groups.
Monotherapy antidepressant and anxiolytic users
reported being prescribed with the medication for
reasons consistent with depression and anxiety,
respectively. However, these analyses focus on a
cohort that, by definition, endorsed almost no symp-
toms consistent with syndromal depressive or anxiety
disorders in their clinical assessment. The average
PHQ-9 score for the antidepressant users was just
1.9 (SD 1.4), where 10 is the screening cutoff for major
depressive disorder (Kroenke et al., 2001). Compared
with the monotherapy group, the combination
therapy patients were more likely to report a past
history of depression as well as reporting depression
as the indication for the prescription. However, the
combination did not endorse any more mental health
Table 2 Self-report of prescription indication for participants on antidepressant or anxiolytic monotherapy
Self-reported reason
Monotherapy
n=167
Antidepressant
n=86 (51.5%)
Anxiolytic
n=81 (48.5%) X2, p-valuea
Anxiety (stress, tension, worry, and nervousness) 82 (49.1) 26 (30.2) 56 (69.1) 25.26, p<0.001
Depression (low mood and lack of interest) 35 (21.0) 32 (37.2) 3 (3.7) p*<0.001
Stressful life event, adjustment, and grief 1 (0.6) 0 (0) 1 (1.2) p* = 0.49
Sleep difficulties 33 (19.8) 11 (12.8) 22 (27.2) 5.43, p=0.02
Pain 16 (9.6) 12 (14.0) 4 (4.9) p* = 0.06
Physical/somatic condition 16 (9.6) 7 (8.1) 9 (11.1) 0.43, p=0.51
Irritability (agitation amd anger) 0 (0) 0 (0) 0 (0) n/a
Cognitive/memory difficulties 2 (1.2) 2 (2.3) 0 (0) p* = 0.50
Miscellaneous 12 (7.2) 6 (7.0) 6 (7.4) 0.01, p=0.91
Reason unknown (e.g., “don’t know”) 3 (1.8) 3 (3.5) 0 (0) p* = 0.25
ad.f. = 1 for all comparisons.
*Fisher’s exact test.
Table 3 Sociodemographic and clinical characteristics of Pharmaceutical Assistance Contract for the Elderly participants on psychotropic
monotherapy versus combination therapy
Characteristic
All interviewees
n=254
Monotherapy^
n=167 (65.7%)
Combination
n=87 (34.3%) Test, p-value
Age (mean, SD) 78.5 (6.4) 78.6 (6.6) 78.3 (6.1) Z=0.25, p=0.81
Female 211 (83.1) 138 (82.6) 73 (83.9) X2(1) = 0.07, p=0.80
White 239 (94.1) 156 (93.4) 83 (95.4) p* = 0.60
Financial Status (has at least “enough to get by”) 235 (92.5) 157 (94.0) 78 (89.7) X2(1) = 1.57, p=0.21
Married 68 (26.8) 47 (28.1) 21 (24.1) X2(1) = 0.47, p=0.49
Number of unique medications, 6months prior to
index medication
7.8 (4.0) 7.5 (4.1) 8.5 (3.9) Z=2.13, p=0.03
Number of unique mediations, 6months after
index medication
7.3 (4.1) 7.0 (4.1) 8.0 (4.1) Z=1.88, p=0.06
Overall general functioning (SF-12): physical component
score (mean, SD)
44.3 (10.6) 44.6 (10.2) 43.8 (11.3) Z=0.42, p=0.67
Overall general functioning (SF-12): mental component
score (mean, SD)
56.5 (5.9) 56.7 (5.7) 56.1 (6.2) Z=.45, p=0.66
In mental health care in past 2 years 6 (2.4) 2 (1.2) 4 (4.6) p* = 0.19
In mental health care in past 3months 3 (1.2) 1 (0.6) 2 (2.3) p* = 0.27
Past history of depression 14 (5.5) 3 (1.8) 11 (12.6) p*<0.001
Cognitive function (blessed score) (mean, SD) 4.9 (3.8) 5.0 (3.8) 4.7 (3.8) Z=0.60, p=0.55
PHQ-9 score (mean, SD) 1.9 (1.4) 1.9 (1.4) 1.9 (1.4) Z=0.41, p=0.68
GAD-7 score (mean, SD) 0.9 (1.2) 0.8 (1.1) 1.1 (1.3) Z=1.85, p=0.07
PHQ-9, Patient Health Questionnaire-9; GAD-7, Generalized Anxiety Disorder-7; SD, standard deviation.
^This monotherapy group is the 86 antidepressant users and 81 anxiolytic users presented in Tables 1 and 2.
*Fisher’s exact test.
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care utilization nor was their depression or anxiety
symptom burden any higher.
While we are not seeking to describe the prevalence
of low-symptom prescribing, our patient-level find-
ings are consistent with recent secondary analyses of
psychotropic use in the absence of a psychiatric
diagnosis. Using a private insurance claims database,
Wiechers et al. recently reported that 58% of individ-
uals prescribed with a psychotropic medication in
2009 had no psychiatric diagnosis (Wiechers et al.,
2014). In data from the Veterans Health Administra-
tion, 30% of the patients had no psychiatric diagnosis.
This was most common in older adults, where
approximately 60% of patients over 65 in non-mental
health practices did not have a psychiatric diagnosis
(Wiechers et al., 2013). Analyses of the National
Ambulatory Medical Care Survey have also found that
prescribing in the absence of a psychotropic diagnosis
is more pronounced in older adults (Maust et al.,
2014)
A key limitation of these analyses is that the baseline
telephone clinical assessment is not performed at
the same time as the prescribing clinician’s assessment
of the patient, so we do not capture the clinical
presentation that prompts the prescription. Given
time-to-onset of psychotropic response, particularly
of antidepressants in older adults, it is unexpected that
participants would essentially be symptom-free by the
time of BHL contact, although benzodiazepine
response is more rapid. Our sensitivity analyses do
not suggest that the symptom burden varies by the
speed of contact. A second limitation is that we do
not know to what extent the enrollees we contact are
representative of those who we are unable to contact
or who are unwilling to participate. Those unwilling
to participate may have had a higher symptom
burden; on the other hand, those that could not be
contacted may have been more active and therefore
more difficult to contact. It is unclear in what way this
non-response may bias our results relative to the true
prevalence of low-symptom prescribing. Lastly, it
may be that the PHQ-9 and GAD-7 are not fully cap-
turing the actual burden of psychiatric symptoms.
However, the SF-12 mental component score is above
50 for all monotherapy and combination therapy
groups, which means these enrollees all reported
above-average mental well-being (Ware et al., 1996),
consistent with their low PHQ-9 and GAD-7 scores.
Conclusion
Going forward, older patients in primary care prac-
tices may be more receptive to psychotropic medica-
tion than the current population of older adults, as
opinions toward psychotropic medications generally
become more favorable (Mojtabai, 2009). As prescrib-
ing increases, potentially inappropriate use of psycho-
tropic medication in the absence of significant
psychiatric symptoms will likely become more com-
mon. Although the emphasis on under-diagnosis and
under-treatment is important, providers should also
recognize that medications are not benign, and there
are risks associated with poorly targeted treatment.
Going forward, it will be important to use patient-level
clinical data in other populations and care systems to
replicate our finding of psychotropic use in these
minimally symptomatic older adults. In addition, as
older adults generally seek care for mental health
needs in primary care settings, it is important that
primary care providers receive more training in the
diagnosis and treatment of mental health disorders
Table 4 Self-report of prescription indication for participants on psychotropic monotherapy versus combination therapy
Self-reported reason
All interviewees
n=254
Monotherapy^
n=167 (65.7%)
Combination
n=87 (34.3%) X2, p-valuea
Anxiety (stress, tension, worry, and nervousness) 119 (46.9) 82 (49.1) 37 (42.5) 0.99, p=0.32
Depression (low mood and lack of interest) 70 (27.6) 35 (21.0) 35 (40.2) 10.64, p<0.01
Stressful life event, adjustment, and grief 2 (0.8) 1 (0.6) 1 (1.1) p* = 1.00
Sleep difficulties 50 (19.7) 33 (19.8) 17 (19.5) 0.00, p=0.97
Pain 21 (8.3) 16 (9.6) 5 (5.7) p* = 0.35
Physical/somatic condition 21 (8.3) 16 (9.6) 5 (5.7) p* = 0.35
Irritability (agitation and anger) 0 (0) 0 (0) 0 (0) n/a
Cognitive/memory difficulties 2 (0.8) 2 (1.2) 0 (0) p* = 0.55
Miscellaneous 16 (6.3) 12 (7.2) 4 (4.6) p* = 0.59
Reason unknown (e.g., “don’t know”) 5 (2.0) 3 (1.8) 2 (2.3) p* = 1.00
^This monotherapy group is the 86 antidepressant users and 81 anxiolytic users presented in Tables 1 and 2.
ad.f. = 1 for all comparisons.
*Fisher’s exact test.
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(Institute of Medicine, 2012). As implementation of
mental health parity and population-based care
continues, it will be essential to implement models of
collaborative care for late-life mental health disorders
that can support primary care providers and increase
the sensitivity and specificity of treatment efforts
(Bao et al., 2013; Katon and Unutzer, 2013; Maust
et al., 2013b).
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